VICP Vicapsys Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $15,267 | $13,097 |
| SG&A expense | $96,431 | $60,198 |
| Operating income | -$1.05M | -$984,790 |
| Interest expense | $19,969 | — |
| Pretax income | -$1.18M | -$984,790 |
| Net income | -$1.18M | -$984,790 |
| EPS (basic) | -0.03 | -0.03 |
| EPS (diluted) | -0.03 | -0.03 |
| Weighted avg. shares (diluted) | 34.55M | 30.58M |
| Balance sheet | ||
| Cash & equivalents | $9,422 | $14,097 |
| Current assets | $39,656 | $72,021 |
| Total assets | $39,656 | $72,021 |
| Current liabilities | $1.97M | $1.02M |
| Short-term debt | $18,712 | — |
| Total liabilities | $1.97M | $1.02M |
| Shareholders' equity | -$1.93M | -$950,791 |
| Shares outstanding | 32.07M | 31.19M |
| Cash flow statement | ||
| Operating cash flow | -$417,524 | -$238,197 |
| Financing cash flow | $412,849 | $34,999 |
| Stock-based compensation | $20,697 | $105,650 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.